Phenothiazine was predicted to interact with the androgen receptor (AR; hsa:367) based on its transcriptional similarity with enzalutamide (D10218), which is marketed for the treatment of prostate cancer and is known to interact with AR. This evidence concerns the gene AR and prostate cancer.